COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT WITH ABALOPARATIDE FOLLOWED BY ALENDRONATE VS ALENDRONATE MONOTHERAPY FOR THE PREVENTION OF FRACTURES IN POSTMENOPAUSAL US WOMEN AT INCREASED RISK OF FRACTURE

被引：0
|
作者：
Hiligsmann, M. [1 ]
Williams, S. [2 ]
Fitzpatrick, L. [2 ]
Silverman, S. [3 ]
Weiss, R. J. [2 ]
Reginster, J. Y. [4 ]
机构：
[1] Maastricht Univ, Maastricht, Netherlands
[2] Radius Hlth Inc, Waltham, MA USA
[3] Univ Calif Los Angeles, Med Ctr, Cedars Sinai, Beverly Hills, CA USA
[4] Univ Liege, Liege, Belgium
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.1136
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS26
引用
收藏
页码：S243 / S243
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT WITH ABALOPARATIDE FOLLOWED BY ALENDRONATE VS. ALENDRONATE MONOTHERAPY FOR USA WOMEN AT INCREASED RISK OF FRACTURE
    Hiligsmann, M.
    Williams, S. A.
    Fitzpatrick, L. A.
    Silverman, S.
    Weiss, R.
    Reginster, J. -Y.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S503 - S504
  • [2] Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective
    Hiligsmann, Mickael
    Williams, Setareh A.
    Fitzpatrick, Lorraine A.
    Silverman, Stuart S.
    Weiss, Richard
    Reginster, Jean-Yves
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (03) : 394 - 400
  • [3] COMPARISON OF THE COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT WITH ABALOPARATIDE FOLLOWED BY ALENDRONATE BETWEEN US WOMEN AND MEN AT INCREASED RISK OF FRACTURE
    Hiligsmann, M.
    Silverman, S.
    Singer, A. J.
    Pearman, L.
    Wang, Y.
    Caminis, J.
    Reginster, J. Y.
    VALUE IN HEALTH, 2023, 26 (06) : S84 - S84
  • [4] Cost-Effectiveness of Sequential Treatment with Abaloparatide Followed by Alendronate in US Men at High Risk of Fracture
    Hiligsmann, Mickael
    Silverman, Stuart
    Singer, Andrea J.
    Pearman, Leny
    Mathew, Jake
    Wang, Yamei
    Caminis, John
    Reginster, Jean-Yves
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2582 - 2583
  • [5] COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT WITH ABALOPARATIDE VS. TERIPARATIDE FOR THE PREVENTION OF OSTEOPOROTIC FRACTURES IN POSTMENOPAUSAL US WOMEN AT INCREASED RISK OF FRACTURE
    Hiligsmann, M.
    Williams, S. A.
    Fitzpatrick, L. A.
    Silverman, S.
    Weiss, R.
    Reginster, J. -Y.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S314 - S314
  • [6] Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures
    Hiligsmann, Mickael
    Silverman, Stuart
    Singer, Andrea J.
    Wang, Yamei
    Pearman, Leny
    Caminis, John
    Reginster, Jean-Yves
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3970 - 3971
  • [7] COST-EFFECTIVENESS OF ABALOPARATIDE FOLLOWED BY ALENDRONATE IN US WOMEN AND MEN AT HIGH RISK OF OSTEOPOROTIC FRACTURES
    Hiligsmann, M.
    Silverman, S.
    Singer, A. J.
    Pearman, L.
    Wang, Y.
    Caminis, J.
    Reginster, J. Y.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S55 - S55
  • [8] Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
    Le, Quang A.
    Hay, Joel W.
    Becker, Russell
    Wang, Yamei
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 134 - 143
  • [9] Cost-Effectiveness of Sequential Abaloparatide/Alendronate for US Women and Men With Osteoporosis and a Recent Vertebral Fracture
    Hiligsmann, Mickael
    Silverman, Stuart
    Singer, Andrea J.
    Pearman, Leny
    Wang, Yamei
    Caminis, John
    Reginster, Jean-Yves
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2023, 30 (12): : 1257 - 1258
  • [10] Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States
    Mickaël Hiligsmann
    Stuart S. Silverman
    Andrea J. Singer
    Leny Pearman
    Jake Mathew
    Yamei Wang
    John Caminis
    Jean-Yves Reginster
    PharmacoEconomics, 2023, 41 : 819 - 830
12345